Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07130097 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants
A Phase 1 study of Healthy Participant, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07130097 is a Phase 1 study of Healthy Participant that has completed, run by Pfizer. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07130097, a Phase 1 study of Healthy Participant, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of the current PF-07220060 tablet formulation and the proposed higher drug load tablet that is already available in the market. The study is seeking participants who are: * Healthy males and females aged 18 to 65 years * Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures. * Body Mass Index of 17.5-30.5 kilogram per meter squared (kg/m2); and a total body weight of more than 50 kilograms (kg) \[110 pounds (lb)\]. Participants in the study will receive a single dose of PF-07220060 by mouth after a meal, following at least 7 days, the participant will then receive another dose of PF-07220060. Each dose received by the participant will be a different tablet formulation, and the sequence of tablet formulations given will be random (just like a flipside of the coin). The study will help the team understand how the difference in tablet formulation may, or may not, affect how the medicine is absorbed, processed, and removed by the body. Participants will remain in the study clinic for at least 13 days and will have one follow-up contact.
Conditions Studied
Interventions
- DRUG PF-07220060
Study Locations (1)
Connecticut
- Pfizer Clinical Research Unit - New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2025-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07130097
The ClinicalTrials.gov registry entry for NCT07130097 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participant appearing as the primary indexed condition, and to 1 intervention - of which PF-07220060 is the first listed.
NCT07130097 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07130097 about?
NCT07130097 is a clinical study titled "A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants". The purpose of this study is to understand bioequivalence (medicines that may have different names or be made in different ways, but have the same effect on the body) of the current PF-07220060 tablet formulation and the proposed higher drug load tablet that is already available in the market. The ...
What is the current status of trial NCT07130097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2025-08-14. Estimated completion is 2025-11-18.
What conditions does trial NCT07130097 study?
This clinical trial studies the following conditions: Healthy Participant.
What interventions are being tested in trial NCT07130097?
The interventions under investigation include: PF-07220060 (DRUG).
Who is sponsoring clinical trial NCT07130097?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07130097 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.